Canaccord Genuity assumed coverage on shares of Sientra, Inc. (NASDAQ:SIEN) in a research note published on Monday morning. The firm issued a buy rating and a $14.00 price objective on the medical instruments supplier’s stock.

Several other equities analysts have also weighed in on the company. Zacks Investment Research lowered Sientra from a hold rating to a sell rating in a report on Tuesday, August 15th. Lake Street Capital restated a buy rating and set a $15.00 target price (up from $11.00) on shares of Sientra in a report on Tuesday, August 8th. Stephens began coverage on Sientra in a report on Tuesday, July 11th. They set an overweight rating and a $12.00 target price on the stock. Finally, ValuEngine upgraded Sientra from a sell rating to a hold rating in a report on Thursday, June 22nd. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of $13.67.

Sientra (NASDAQ SIEN) opened at 11.13 on Monday. Sientra has a 52 week low of $6.92 and a 52 week high of $11.47. The stock’s market cap is $214.88 million. The stock has a 50 day moving average price of $10.63 and a 200 day moving average price of $9.08.

Sientra (NASDAQ:SIEN) last posted its earnings results on Wednesday, August 9th. The medical instruments supplier reported ($0.55) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.04. Sientra had a negative return on equity of 52.30% and a negative net margin of 173.83%. The company had revenue of $8.20 million for the quarter, compared to analyst estimates of $6.97 million. Sientra’s revenue for the quarter was up 32.3% on a year-over-year basis. On average, equities analysts predict that Sientra will post ($3.04) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/sientra-inc-sien-receives-new-coverage-from-analysts-at-canaccord-genuity/1529383.html.

Several institutional investors have recently bought and sold shares of SIEN. California State Teachers Retirement System acquired a new position in Sientra during the second quarter worth approximately $246,000. State Street Corp acquired a new position in Sientra during the second quarter worth approximately $1,449,000. Cloverdale Capital Management LLC raised its position in Sientra by 28.9% in the second quarter. Cloverdale Capital Management LLC now owns 492,237 shares of the medical instruments supplier’s stock worth $4,785,000 after buying an additional 110,495 shares during the last quarter. Bamco Inc. NY raised its position in Sientra by 109.3% in the second quarter. Bamco Inc. NY now owns 471,500 shares of the medical instruments supplier’s stock worth $4,583,000 after buying an additional 246,183 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Sientra by 23.4% in the second quarter. Dimensional Fund Advisors LP now owns 18,660 shares of the medical instruments supplier’s stock worth $181,000 after buying an additional 3,534 shares during the last quarter. Institutional investors and hedge funds own 77.61% of the company’s stock.

Sientra Company Profile

Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.

Receive News & Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.